NASDAQ$BNTX
BioNTech SE-ADR · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
BioNTech reported a net loss and decreased revenue compared to Q1 2024, as expected due to seasonal demand for COVID-19 vaccines.
BioNTech's Q1 2025 results showed a net loss of €415.8 million on revenues of €182.8 million, primarily driven by reduced COVID-19 vaccine demand. The company continued advancing its oncology pipeline and maintained a strong cash position.
- Revenue declined slightly to €182.8 million, mainly from COVID-19 vaccine collaboration.
- Reported a net loss of €415.8 million and an EPS of -€1.73.
- Strong financial position with €15.85 billion in cash and investments.
- Focus remains on oncology programs, especially BNT327 combinations.
Headline financials
Revenue & EPS history
BioNTech SE · Revenue · Quarterly
$198M
Forward guidance
BioNTech expects total 2025 revenues between €1.7 billion and €2.2 billion, with revenue weighted toward year-end.
Tailwinds
- Full-year revenue guidance reaffirmed.
- Strong financial position enables continued investment in oncology.
- Anticipated pandemic preparedness revenue from German government.
- Reimbursement of $535 million expected in 2025–2026 for settlements.
- Continued scaling for late-stage oncology commercial readiness.
Headwinds
- No expectation of positive net income for FY2025.
- Vaccine demand concentrated in later months creates revenue timing risk.
- Potential inventory write-downs by partner Pfizer may impact revenue.
- Dependent on stable vaccination rates and public health policy.
- External legal risks and one-time effects excluded from guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+6.5%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+13.8%
Q4 2020
Best reaction
-14.6%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2025 | -3.7% | -5.3% | — | |
| Q2 2025 | +2.5% | +4.0% | -6.4% | |
| Q4 2024 | -3.2% | -8.6% | -13.5% | |
| Q3 2024 | -0.5% | -0.8% | +2.9% | |
| Q1 2024 | -2.0% | -1.1% | +10.5% | |
| Q4 2023 | -2.3% | -1.2% | -7.8% | |
| Q3 2023 | +6.9% | +3.9% | +5.8% | |
| Q2 2023 | -4.4% | +0.4% | +12.8% | |
| Q1 2023 | -3.5% | -2.9% | +0.9% | |
| Q4 2022 | -4.1% | -2.8% | -13.7% | |
| Q3 2022 | +4.3% | +0.1% | +5.4% | |
| Q2 2022 | -14.1% | -12.4% | -21.3% | |
| Q4 2021 | -1.1% | +16.6% | +18.8% | |
| Q1 2022 | +6.1% | +16.6% | +18.8% | |
| Q3 2021 | -3.0% | -1.8% | +17.2% | |
| Q2 2021 | +7.1% | -3.0% | -13.6% | |
| Q1 2021 | +7.8% | +4.9% | +31.5% | |
| Q4 2020 | +13.8% | +10.8% | +38.9% | |
| Q3 2020 | +4.4% | +1.1% | +23.6% | |
| Q2 2020 | -6.5% | -7.2% | -17.2% | |
| Q1 2020 | -3.0% | -1.0% | -2.8% | |
| Q4 2019 | -14.6% | -14.9% | -23.4% | |
| Q3 2019 | +3.7% | +9.6% | +74.9% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro